Merck to Acquire Terns for $6.7B to Fortify Oncology Pipeline
Key Takeaways
- Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, a strategic move designed to diversify its oncology portfolio.
- The acquisition comes as Merck prepares for the impending patent expiration of its top-selling cancer immunotherapy, Keytruda, later this decade.
Key Intelligence
Key Facts
- 1Merck is acquiring Terns Pharmaceuticals in an all-cash deal valued at $6.7 billion.
- 2The acquisition is specifically aimed at bolstering Merck's oncology pipeline ahead of the 2028 Keytruda patent cliff.
- 3Keytruda currently accounts for more than 40% of Merck's total annual revenue.
- 4Terns' lead oncology asset, TERN-701, is a clinical-stage treatment for chronic myeloid leukemia (CML).
- 5The deal follows Merck's broader strategy of diversifying into small-molecule and targeted therapies.
- 6The transaction is expected to close in the second half of 2026, pending regulatory approval.
Who's Affected
Analysis
Merck’s $6.7 billion acquisition of Terns Pharmaceuticals marks a pivotal moment in the company’s strategy to navigate the looming 'patent cliff' of its blockbuster drug, Keytruda. As the world’s top-selling cancer immunotherapy, Keytruda has been the cornerstone of Merck’s revenue for years, generating over $25 billion annually. However, with its primary patents set to expire in 2028, Merck is under immense pressure to secure new growth drivers that can offset the inevitable influx of biosimilar competition. This acquisition is not merely an expansion; it is a defensive necessity aimed at maintaining Merck’s dominance in the global oncology market.
Terns Pharmaceuticals brings a specialized pipeline of small-molecule therapies that complement Merck’s existing strengths in biologics. A key asset in the deal is TERN-701, an allosteric BCR-ABL inhibitor currently in clinical development for chronic myeloid leukemia (CML). Unlike traditional kinase inhibitors, TERN-701 is designed to target a specific pocket of the ABL protein, potentially offering a better safety profile and overcoming resistance seen with earlier-generation treatments. By integrating Terns’ oral small-molecule expertise, Merck is diversifying its therapeutic modalities, moving beyond the injectable PD-1 inhibitors that have defined its recent success.
Merck’s $6.7 billion acquisition of Terns Pharmaceuticals marks a pivotal moment in the company’s strategy to navigate the looming 'patent cliff' of its blockbuster drug, Keytruda.
The $6.7 billion price tag reflects the high premium currently placed on clinical-stage biotech assets with de-risked data. For Merck, this deal follows a pattern of targeted acquisitions, such as its previous purchases of Acceleron Pharma and Prometheus Biosciences, which were also aimed at filling the post-2028 revenue gap. Industry analysts view the Terns deal as a logical step in building a multi-layered oncology franchise. By owning both the leading immunotherapy and a suite of targeted small molecules, Merck can explore combination therapies that could extend the clinical utility of its portfolio and create new patent-protected treatment regimens.
What to Watch
Beyond oncology, Terns has also been active in the metabolic space, developing treatments for MASH (metabolic dysfunction-associated steatohepatitis) and obesity. While Merck’s primary focus in this deal is oncology, the metabolic pipeline offers additional upside in two of the fastest-growing sectors of the pharmaceutical industry. The ability to leverage Terns’ platform for both cancer and metabolic health provides Merck with a broader surface area for long-term growth, though the immediate priority will remain the successful transition of Terns’ cancer candidates through late-stage clinical trials.
Looking ahead, the success of this acquisition will hinge on the clinical performance of Terns’ lead assets over the next 24 months. Investors will be closely watching for Phase 2 and Phase 3 data readouts, as any setbacks in the pipeline would heighten concerns regarding Merck’s post-Keytruda future. Furthermore, the deal will likely face regulatory scrutiny as the Federal Trade Commission (FTC) continues to monitor consolidation in the pharmaceutical industry. However, given that Terns’ assets are largely complementary rather than overlapping with Merck’s current products, the path to regulatory approval is expected to be manageable. This acquisition signals to the market that Merck is willing to spend aggressively to protect its leadership, setting the stage for a high-stakes transformation of its clinical portfolio as the 2028 deadline approaches.
Timeline
Timeline
Acquisition Announced
Merck and Terns Pharmaceuticals announce a definitive $6.7 billion merger agreement.
Expected Closing
Anticipated completion of the acquisition following regulatory and shareholder approvals.
Pipeline Integration
Merck integrates Terns' small-molecule oncology candidates into its global R&D infrastructure.
Keytruda Patent Expiration
The primary patent for Merck's blockbuster drug Keytruda expires, opening the door for biosimilars.
Sources
Sources
Based on 2 source articles- abcnews.comMerck buying Terns in $6 . 7B deal to bolster its cancer portfolio before key Keytruda patent expiresMar 25, 2026
- clickorlando.comMerck buying Terns in $6 . 7B deal to bolster its cancer portfolio before key Keytruda patent expiresMar 25, 2026
How we covered this story
Every story in our healthcare coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the healthcare space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled healthcare-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |